大盘表现上，稳定币概念股多数走高。截至收盘，耀才证券金融、云锋金融、移卡等相关股票上涨10% 以上。开源证券指出，全球监管政策逐渐完善，有望推动稳定币产业合规稳健发展，将催化产业新的投 资机遇。 同时，受政策利好驱动，当日医药股、保险股等同样走强。其中，三叶草生物、乐普生物、歌礼制药等 医药股的上涨幅度超过60%。 7月18日，香港恒生指数收市报24825.66点，上升326.71点，升幅为1.33%，全日成交金额为2386.91亿港 元。中新社记者 李志华 摄 来源：中国新闻网 中新社香港7月18日电 (记者 刘大炜)7月第三个交易周，在稳定币概念股、医药股等持续活跃的推动 下，港股相关指数延续反弹。截至18日收盘，香港恒生指数累涨2.84%，国企指数累涨3.44%，恒生科 技指数累涨5.53%。 从全周走势来看，恒生指数、恒生科技指数均一路攀升至高点。18日，香港恒生指数收报24825.66点， 涨1.33%；国企指数涨1.51%，报8986.47点；恒生科技指数涨1.65%，报5538.83点。 此外，香港特区政府公司注册处18日发表的统计数字显示，截至今年6月底，本地公司总数和非香港公 司总数均创历史 ...

（原标题：揭秘涨停丨最高8连板，这些牛股获资金追捧） 今日（7月18日），A股市场收盘共52股涨停，剔除掉6只ST板块个股后，有46股涨停，21股封板未遂，整体封板率为71.23%。 涨停战场：上纬新材封单资金超9亿元 从收盘涨停板封单量来看，人民同泰封单量最高，有39.36万手；其次是上纬新材、美邦股份、中色股份、延华智能，涨停板封单分别为28.07万 手、22.24万手、22.09万手、18.11万手。 从连续涨停天数来看，上纬新材8连板，兰生股份6连板，*ST恒久5连板，天宸股份、海星股份、*ST威尔3连板，人民同泰、美邦股份、延华智能 等8股2连板，柳钢股份4日3板等。 以封单金额计算，13股封单资金超1亿元，上纬新材、美邦股份、人民同泰封单资金居前，分别为9.39亿元、5.19亿元、3.64亿元。 涨停个股：金圆股份、国机通用、久吾高科、盛新锂能 7月18日碳酸锂期货2509合约上涨2.82%，近20个交易日上涨17.42%。 金圆股份：公司捌千错盐湖提锂项目处于试生产阶段。 国机通用：公司开发研制出的三元锂电池材料过滤洗涤一体机，在多家锂电材料生产企业应用。 久吾高科：公司现有的盐湖提锂产品及技术 ...

Core Viewpoint - The article highlights the successful secondary listing of Kangzheng Pharmaceutical Holdings Limited on the Singapore Exchange, facilitated by China Galaxy Securities, marking a significant milestone for the company and reflecting the growing trend of Chinese enterprises seeking opportunities in Southeast Asia amid complex international market conditions [2][5][6]. Group 1: Market Context - The international capital market environment has become increasingly complex, with geopolitical and regulatory uncertainties posing significant challenges for some Chinese concept stocks [3]. - Southeast Asia has emerged as a preferred destination for Chinese enterprises to expand overseas, driven by strong economic growth, market potential, and geographical advantages [3]. - The strategic value of capital markets is becoming more pronounced as Chinese companies transition from "product export" to "industrial chain export," leading to increased demand for cross-border financing and M&A services [3]. Group 2: Kangzheng Pharmaceutical's Strategy - Kangzheng Pharmaceutical aims to leverage its secondary listing in Singapore as a strategic pivot to deepen its presence in Southeast Asia [4]. - The company has established differentiated advantages in various therapeutic areas, including cardiovascular, central nervous system, digestive, skin, and ophthalmology since its initial listing in Hong Kong in 2010 [4]. - The listing is viewed as a critical milestone in the company's history, intended to accelerate its internationalization strategy and enhance its global footprint [5]. Group 3: Role of China Galaxy Securities - China Galaxy Securities has played a pivotal role in facilitating the secondary listing of Kangzheng Pharmaceutical, showcasing its capabilities in navigating complex regulatory environments and providing tailored financial services [6][7]. - The firm has a significant local presence in Southeast Asia, with over 2,000 employees and more than 70 researchers, enabling it to understand market nuances and regulatory requirements effectively [7]. - The successful listing of Kangzheng Pharmaceutical follows the previous success of another company, Helen's, indicating a replicable and sustainable model for supporting Chinese enterprises in their international expansion [8]. Group 4: Broader Financial Services - China Galaxy Securities has extended its services beyond IPOs and the Singapore Exchange, successfully assisting various companies in cross-border financing, mergers, and acquisitions [9][10]. - The firm has facilitated significant projects for diverse industries, demonstrating its comprehensive service capabilities in addressing complex financial needs for both Chinese and Southeast Asian enterprises [10]. - As the internationalization of Chinese enterprises accelerates, China Galaxy Securities is positioned to continue playing a crucial role in connecting these companies with global opportunities [11].

"港交所的铜锣快不够用了。"这句投资者的调侃，正成为港股IPO（首次公开募股）市场火爆最为显性的一面。 7月9日，港交所金融大会堂6面铜锣齐鸣，创下年内上市公司数量纪录，也创下港交所铜锣数量新高，原本在香港各区巡礼展 览的铜锣都被拉回来摆在现场。 当日，峰岹科技（688279.SH）、极智嘉（2590.HK）、讯众通信（2597.HK）、大众口腔（2651.HK）、蓝思科技 （6613.HK）5家公司同日登陆港交所主板，恒生摩根美国股票高入息主动型ETF亦同日上市，金融大会堂首现六锣同鸣。 据万得（Wind）数据，2025年上半年，港股市场的IPO募资额高达1067亿港元，是去年同期的近8倍，重返全球第一。从上市 时间分布来看，5月与6月为上半年新股上市的集中时段，期间共有25家企业完成IPO，占上半年上市总量的58.14%。而2月、4 月分别仅有1家和2家企业实现上市，为上半年上市数量最少的两个月份。 从募资情况来看，实际募资额超过20亿港元的新股有8只，超过10亿港元的有17只。其中，实际募资总额前五名的分别为宁德 时代、恒瑞医药、海天味业、三花智控与蜜雪冰城，募资总额分别为410.06亿港元、113.7 ...

Market Overview - Hong Kong stocks experienced a rebound with all three major indices rising over 1%, closing with the Hang Seng Index up 1.33% at 24,825.66 points and a total trading volume of HKD 238.69 billion [1] - For the week, the Hang Seng Index increased by 2.84%, the Hang Seng China Enterprises Index rose by 3.44%, and the Hang Seng Tech Index gained 5.53% [1] - The recent geopolitical tensions in the Middle East have eased, and there is a marginal improvement in US-China relations, contributing to a recovery in global market risk appetite [1] Blue Chip Performance - ZTO Express (02057) led blue-chip stocks with a rise of 6.51%, closing at HKD 152.1, contributing 6.54 points to the Hang Seng Index [2] - China Life (02628) increased by 5.13%, contributing 11.32 points, while Hansoh Pharmaceutical (03692) rose by 4.49%, contributing 2.86 points [2] - Xinyi Solar (00968) fell by 3.41%, detracting 0.75 points from the index, and Galaxy Entertainment (00027) decreased by 0.93%, detracting 1.2 points [2] Sector Highlights Stablecoin Sector - Stablecoin-related stocks saw significant gains following the US Congress's approval of the Stablecoin Innovation Act, with Yao Cai Securities Financial (01428) rising by 16.93% and Yunfeng Financial (00376) up by 15% [3] - The act aims to establish a clear legal framework for stablecoins, which is expected to enhance the compliance and development of the stablecoin industry [3] AI Sector - AI-related stocks were active, with Huya Technology (01860) rising by 15.56% and Innovation Works (02121) increasing by 10.39% [4] - The recent launch of the K2 model by Moonlight Kimi and OpenAI's ChatGPT Agent has sparked interest in AI advancements, with analysts optimistic about the sector's growth potential [4] Pharmaceutical Sector - The pharmaceutical sector showed strong performance, with Lepu Biopharma (02157) surging by 24.65% and Genscript Biotech (01672) rising by 17.97% [4] - Morgan Stanley noted a significant rebound in China's healthcare sector, with the MSCI China Healthcare Index up approximately 50% this year [5] Brokerage and Insurance Stocks - Brokerage and insurance stocks also saw gains, with GF Securities (01776) up by 5.04% and China Life (02628) increasing by 5.13% [6] - Recent policies aimed at guiding insurance funds towards long-term stable investments are expected to enhance the profitability of insurance companies [6] Notable Stock Movements - China New Economy Investment (00080) surged by 394.38% after announcing a mandatory cash offer for shares [7] - Chuangmeng Tiandi (01119) rose by 30.12% following a profit forecast indicating a turnaround [8] - Dongfang Zhenxuan (01797) increased by 12.78% due to new product launches [9] - CATL (03750) reached a new high, with Goldman Sachs projecting strong revenue and profit growth [10] - Kintor Pharmaceutical (01888) fell by 9.23% after announcing a share placement at a discount [11]

Group 1 - Four companies, including Dongshan Precision, Yanghe Brewery, Hudian Co., and Hengli Hydraulic, have recently surpassed a market capitalization of 100 billion yuan, with Jiangsu province having a total of 10 such companies as of July 18 [1][2] - Dongshan Precision's stock price hit a ceiling on July 17, closing at 55.31 yuan per share, resulting in a market capitalization of 101.3 billion yuan. The company has developed three main sectors: electronic circuits, optoelectronics, and precision manufacturing, ranking second globally in flexible printed circuits (FPC) and third in PCBs based on revenue [1] - Hudian Co. saw an 8.59% increase in stock price on July 17, bringing its market capitalization to 102.2 billion yuan. The company is expected to achieve a net profit of 1.65 to 1.75 billion yuan in the first half of 2025, marking a year-on-year increase of 44.63% to 53.40% [1] Group 2 - Yanghe Brewery, a well-known domestic liquor company, has returned to the 100 billion yuan club, focusing on its major products like "Hai Zhi Lan" and "Meng Zhi Lan M6+" while planning to launch new products priced above 50 yuan [2] - Hengli Hydraulic's stock price has nearly doubled since January, with its market capitalization exceeding 100 billion yuan again. The company has entered mass production for its linear actuator project, which is expected to drive new growth [2] - In addition to the four companies mentioned, Jiangsu province also has six other companies, including Jiangsu Bank and Huatai Securities, in the 100 billion yuan market capitalization club, highlighting Jiangsu's status as a manufacturing powerhouse [3]

7月16日，在链博会先进制造链展区创新链专区，观众参观展示锂电固体废料高效低碳处理技术与应用 的全景沙盘。 新华社记者 金立旺摄 "热流"涌动，"新意"不断。7月16日，为期5天、以"链接世界、共创未来"为主题的第三届中国国际供应 链促进博览会在北京开幕。 作为全球首个以供应链为主题的国家级展会，连续举办3年，本届链博会也呈现国际范更足、创新味更 浓、"链接度"更高等特点，创新开放"更"上层楼。 国际范更足：世界500强和行业龙头企业占比超65% 空中客车中国公司首次参展，还带来十多家中国供应链伙伴，共同演绎航空产业链上下游的协同合作； 苹果继续与本土供应链伙伴一起参展，展示绿色智能制造、人才培养等方面的成果；GE医疗、诺和诺 德、阿斯利康、赛诺菲、美敦力等一批世界500强医药巨头亮相，全面展示他们在国际合作与本土化创 新方面的新进展……本届链博会，国际范儿十足。 创新是链博会的底色，也是链博会的生命力所在。据主办方介绍，预计展期将有超过100项首发首展首 秀，比上届增加10%。此外，本届链博会迎来了230多家首次参展的中外新伙伴。英伟达、施耐德、欧 莱雅、路易达孚、美敦力等一大批首次参加链博会的跨国公司不仅 ...

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 今 日 聚 焦 【固收】25年上半年可转债评级调整有何特征？——2025年上半年可转债信用评级调整情况回顾 1、25H1债项评级被调整的可转债的评级均为下调，但下调数量同比减少；发行时债项评级以AA-及以下级别 为主；剩余期限普遍集中在1年以内和2~4年。主体评级下调的可转债发行人以民营企业为主；主要集中在基 础化工和计算机等行业。2、25H1评级被调整的可转债发行人普遍盈利能力下滑，现金流弱化，短期偿债压力 较大，流动性风险攀升。公司治理及其他风险上升。 （张旭）2025-07-16 您可点击今日推送内容的第1条查看 【基础化工】COFs：高性能结晶性多孔高分子材料，新能源等领域应用前景可期——COFs行业动态报告 COFs是一类具有 ...

Group 1: Company Performance - Zhongwei Company expects a net profit of 680 million to 730 million yuan for the first half of 2025, representing a year-on-year increase of 31.61% to 41.28% [1] - The company's operating revenue is approximately 4.961 billion yuan, with a year-on-year growth of 43.88%, driven by significant increases in revenue from etching equipment and LPCVD film equipment [1] - Hangzhou Bank reported a net profit of 11.662 billion yuan for the first half of 2025, reflecting a year-on-year growth of 16.67% [2] - The bank's total assets reached 2.235595 trillion yuan, up 5.83% from the end of the previous year [2] Group 2: Corporate Actions - Helen Piano announced that its actual controllers are planning a change in control, leading to a temporary suspension of its stock starting July 18 [3] - Shanghai Material Trade reported that its subsidiary's data product "Non-ferrous Metal Spot Index Query" is currently in a "temporarily invalid" state due to lack of transactions since its listing [4] - Lansheng Co. stated that it has not engaged in any business related to "stablecoins" amid rising market interest [5] Group 3: Other Corporate Developments - Microchip Biotech expects a net profit of 30.06 million yuan for the first half of the year, marking a turnaround from losses [6] - Tuo Jing Technology anticipates a year-on-year net profit increase of 101% to 108% for the second quarter [6] - Kai Sheng New Materials has set an initial inquiry transfer price of 13.69 yuan per share [6]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have announced significant developments, including changes in control, asset sales, investments, and performance forecasts, which may present investment opportunities and risks for investors. Group 1: Control Changes and Major Transactions - Helen Piano's actual controllers are planning a change in control, leading to a suspension of trading starting July 18, 2025, for up to two trading days [3] - Tiger Medical is selling 95.09% of its stake in Lixin Pharmaceutical for approximately $34.11 million [4] - ST Lifan announced that its operational situation has not changed significantly despite a stock price fluctuation of 42.54% over two trading days [9] Group 2: Investments and Acquisitions - Sdic plans to invest approximately 509 million yuan in expanding its high-end functional film production capacity [5] - Dongfang Yuhong's subsidiary intends to acquire 100% of Chile's Construmart for about $123 million [6] - Huaitian Thermal Power has been recommended as the owner of a 700,000 kW wind power project, aligning with its investment strategy [7] Group 3: Performance Announcements - Hangzhou Bank reported a net profit of 11.662 billion yuan for the first half of the year, a year-on-year increase of 16.67% [14] - Tuojing Technology expects a net profit increase of 101% to 108% in Q2 2025, driven by new product breakthroughs [15] - Weicheng Bio anticipates a net profit of 30.06 million yuan for the first half of 2025, reversing a loss from the previous year [17] Group 4: Contracts and Strategic Partnerships - State Grid Information won contracts totaling 966 million yuan from the State Grid Corporation [21] - Beizhi Technology signed a contract worth 164 million yuan with a major client [22] - Mould Technology received a project letter of intent for exterior parts with an expected total sales of 2.044 billion yuan [23] Group 5: Shareholding Changes - Huasheng Lithium plans to reduce its shareholding by up to 2.24% [25] - Yutai Micro's shareholder intends to reduce holdings by up to 3% due to personal funding needs [26] - Alter's controlling shareholder plans to reduce holdings by up to 3% [27]